Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07091734 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Study acronym: TILT-2024
StatusRecruiting
PhasePhase 2
Started2025-09-08
View on ClinicalTrials.gov ↗

Amendment history

2025-09-08
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2029-07→2029-09
Completion date2029-07→2029-09
Start dateestimated 2025-07→confirmed 2025-09-08
Study sitesdetails revised at 1 of 1 site
2025-07-21
Original filing
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study Hypothesis: \- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.
Trial Details
NCT Number NCT07091734
Lead Sponsor University of Michigan
Conditions Lipodystrophy, Partial
Enrollment 32 participants
Start Date 2025-09-08
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-09